Abbott Invests Another $20 Million In Isis Unit
This article was originally published in The Pink Sheet Daily
Executive Summary
The move brings a possible buyout of subsidiary one step closer.
You may also be interested in...
Teva’s Antisense Therapy Meets Phase IIa Endpoint In MS Study
Product licensed from Antisense Therapeutics is under development for reduction in multiple sclerosis-related brain lesions
Isis: Pondering Platform Power
The January 2008 collaboration Isis forged with Genzyme was transformative for Isis and a desperately sought-after validation of the antisense field. But unlike its brethren in oligonucleotide drug development -- and most biotechs, for that matter -- Isis rejects the notion of commercializing its products. The deal sets up a paradox: Can Isis remain a platform company once investors' focus is on a product and its trajectory? In a sense, can it stay small?
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf